Pfizer Inc. (NYSE:PFE) ranks among the best low-risk investments in May 2026. On April 13, Guggenheim reaffirmed a Buy rating and a $36 price target for Pfizer Inc. (NYSE:PFE) as the firm revised its ...
Pfizer Inc. (NYSE:PFE) is one of the 10 Best Medical Stocks to Buy Under $30. On April 20, Pfizer Inc. (NYSE:PFE) announced, ...
Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...
Zacks Investment Research on MSN
Ahead of Pfizer (PFE) Q1 earnings: Get ready with Wall Street estimates for key metrics
Wall Street analysts expect Pfizer (PFE) to post quarterly earnings of $0.74 per share in its upcoming report, which indicates a year-over-year decline of 19.6%. Revenues are expected to be $13.82 ...
StockStory.org on MSN
Pfizer earnings: What to look for from PFE
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors ...
The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question ...
Pfizer (PFE) stock and Arvinas (ARVN) stock are in focus as the FDA approves the companies' breast cancer drug, Veppanu. Read ...
(PFE) is running a Phase 2 trial of ritlecitinib in adults with moderate to severe hidradenitis suppurativa, a chronic skin disease that causes painful lumps. The study, officially titled “A Phase 2, ...
Pfizer Inc. (NYSE:PFE) on Friday released results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle ...
In this article, we will discuss the 9 Most Active US Stocks to Buy Right Now. On April 29, Joe Amato, Neuberger President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results